Search PubMed⌕ Search

Biomedical subjects

W Linkesch

Publications and source records attributed to W Linkesch.

131 records · Page 8Linked to original sources
PubMed1977

[Investigations of the final settling of implanted hip-joints by use of 85Sr (author's transl)].

Up to 8 years after replacement of hip-joints in 26 patients the strontium-85-uptake over both thighs was followed scintimetrically. In contrary to normal healing of fractures, this uptake became normal on the side of the operation not earlier than the end of the 2nd year after operation. One cause of this delay could be the continuing liberation of monomeres of polymethyl-methacrylates at the bed of the implant. It is important to consider the clinical signs on the opposite side, since there a raised strontium-85-uptake could produce a "pseudo"-diminished ratio between the two sides.

Aged↗
PubMedDate not supplied

Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP).

The concentration-time profiles of Doxorubicin (DOXO) from day 0 to day 21 after i.v. infusion of 25 or 30 mg/m2 doxorubicin HCI stealth liposomes (Caelyx) were investigated in 9 patients receiving combination polychemotherapy with cyclophosphamide, vinorelbine and prednisone. Peak serum concentrations occurred from 0.04 to 4.0 days after infusion (mean tmax = 1.79 +/- 1.55 d) with a mean cmax of 4,595 +/- 2,849 ng/ml. A total amount of 12.84 +/- 2.47 mg liposomal DOXO in the plasma volume (Vp = 2,794 + 537 ml) could be estimated at tmax (= 27 % of the mean dose of 47.6 mg). Stealth liposomes were eliminated slowly from the blood with a mean t 1/2el of 1.9 + 0.5 days (MRT was 4.6 + 2.5 days). AUClast values ranged from 8,070 to 33,446 ng/ml*d (mean 10,987 +/- 9,339 ng/ml*d). The low plasma clearance (Cltot = 4,681 +/- 2,835 ml/day) and the small volume of distribution (Vz = 11.7 +/- 6.31) suggested that stealth-liposomes were stable in the blood at least for 14 days. Polychemotherapy with Hyper-CCVP schedule did not alter the stability of stealth liposomes, but peak levels of DOXO seemed to be somewhat lower compared to regression analysis of literature data (cmax versus dosage range from 20 to 60 mg/m2). Due to clast occurring between day 12 to 18, no indices for an accumulation of the drug in the blood could be found, when liposomes were given every four weeks.

Adult↗
PubMedDate not supplied

Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C.

The present analysis was performed to evaluate the impact of cytosine arabinoside (ara-C) dose escalation on hematological and cytogenetic responses in patients with chronic myelogenous leukemia (CML) who failed to respond to low-dose ara-C (LD ara-C) at a dose of 10 mg/m2/d over 10 days per month and interferon-alpha (IFNalpha, 3.5 MU/d). Following the same administration schedule, dose escalation of ara-C to 15 and 20 mg/m2/d 1-10 was performed in 36 of 119 patients (30%) due to inadequate hematological response and/or disease progression. As a result, improvement of hematological and cytogenetic responses was achieved in 22 (61%) and nine (25%) patients, respectively. Escalated ara-C dose levels were usually well tolerated, although some patients experienced deterioration of preexisting side effects. Our results support the critical role of ara-C dose towards a better disease control in CML.

Adolescent↗
PubMedDate not supplied

[Serum ferritin as an indicator for iron substitution in patients with chronic polyarthritis].

20 patients with rheumatoid arthritis were treated with oral iron for 6 months and hematological parameters including serum ferritin levels and iron absorption were studied. 13 patients (group 1) had iron deficiency as estimated by low serum ferritin concentration (less than or equal to 30 micrograms/l); the other 7 patients (group 2) revealed normal ferritin levels. After treatment with oral iron, patients of group 1 show a significant increase in serum ferritin, serum iron, hematocrit, erythrocytes, and hemoglobin, a significant decrease in transferrin, and diminished iron absorption. In contrast, in group 2 there was no change in the above-mentioned parameters. The evaluation of iron stores by serum ferritin levels is limited to patients with inactive rheumatoid arthritis. Patients with active disease show hyperferritinemia which no longer represents the iron stores. In this case patients with active rheumatoid arthritis and iron deficiency could reveal normal serum ferritin values.

Anemia, Hypochromic↗